Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 1.00 |
| ▸ | ITPR2 | Q14571 | 4/20 | 1.00 |
| ▸ | ITPR1 | Q14643 | 4/20 | 1.00 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.84 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.75 |
| ▸ | AKT1 | P31749 | 1/20 | 0.75 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9091859 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9093199 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9094714 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL2510044 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL8994052 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9091912 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL405897 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL8775574 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL2044892 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL9387601 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101686986-A | Cyclitols and derivatives thereof and their therapeutic use | NORMOXYS INC | 2010-03-31 | — | — | CN | claimed |
| EP-2111226-A2 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | Normoxys, Inc. (US) | 2009-10-28 | — | — | EP | claimed |
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | UNIVERSITE DE STRASBOURG (FR) | 2008-08-21 | — | — | US | claimed |
| WO-2008082658-A2 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NORMOXYS, INC. (US) | 2008-07-10 | — | — | WO | claimed |
| EP-0505452-B1 | USE OF INOSITOLPHOSPHATES FOR PREPARING MEDICAMENT | PERSTORP AB (SE) | 1996-06-19 | — | — | EP | claimed |
| US-5342832-A | Use of mono and di inositolphosphates for treating inflammation | PERSTORP AB (SE) | 1994-08-30 | — | — | US | claimed |
| EP-0505452-A1 | USE OF INOSITOLPHOSPHATES FOR PREPARING MEDICAMENT. | PERSTORP AB (SE) | 1992-09-30 | — | — | EP | claimed |
| WO-1991009601-A1 | USE OF INOSITOLPHOSPHATES FOR PREPARING MEDICAMENT | PERSTORP AB (SE) | 1991-07-11 | — | — | WO | claimed |
| EP-4370670-A1 | PHYTASE VARIANTS WITH IMPROVED STABILITY AND IP4 ACTIVITY | AB Enzymes Oy (FI) | 2024-05-22 | — | — | EP | disclosed |
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | TEAM MEDICAL, LLC (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024055011-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | TEAM MEDICAL, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11849740-B2 | Nutritional composition | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-12-26 | — | — | US | disclosed |
| US-11590163-B2 | Iron-fortified food composition | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-02-28 | — | — | US | disclosed |
| US-20230034301-A1 | NUTRITIONAL COMPOSITION | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0505452-B1 | USE OF INOSITOLPHOSPHATES FOR PREPARING MEDICAMENT | PERSTORP AB (SE) | 1996-06-19 | — | — | EP | disclosed |
| US-5342832-A | Use of mono and di inositolphosphates for treating inflammation | PERSTORP AB (SE) | 1994-08-30 | — | — | US | disclosed |
| EP-0505452-A1 | USE OF INOSITOLPHOSPHATES FOR PREPARING MEDICAMENT. | PERSTORP AB (SE) | 1992-09-30 | — | — | EP | disclosed |
| WO-1991009601-A1 | USE OF INOSITOLPHOSPHATES FOR PREPARING MEDICAMENT | PERSTORP AB (SE) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | PPIP5K2, IP6K1, IP6K3 | ITPR3 23/4885ITPR2 20/4885ITPR1 13/4885 |
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | RBM22, HNRNPUL2, HNRNPUL1 | ITPR3 3547/4885ITPR2 3622/4885ITPR1 3238/4885 |
| US-11590163-B2 | Iron-fortified food composition | TFRC, FTH1, HAMP | ITPR3 36/4885ITPR2 80/4885ITPR1 60/4885 |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | ITPR3 1618/4885ITPR2 2725/4885ITPR1 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.